Diagnostyka rearanżacji genu SHOX u kobiet 46,XX z idiopatyczną niskorosłością by Mitka, Magdalena et al.
397
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.a2016.0050
Tom/Volume 67; Numer/Number 4/2016
ISSN 0423–104X
Diagnostics of SHOX gene rearrangement in 46,XX  
women with idiopathic short stature
Diagnostyka rearanżacji genu SHOX u kobiet 46,XX z idiopatyczną niskorosłością
Magdalena Mitka1, Michał Bednarek3, Bogdan Kałużewski3
1Chair of Clinical and Laboratory Genetics, Medical University of Lodz, Poland 
2Department of Clinical Genetics, Clinical-Didactic Centre of the Medical University in Lodz 
3Outpatient Department of Clinical Genetics, Genos Non-Public Healthcare Unit, Lodz, Poland
Abstract
Introduction: The SHOX gene has been mapped at the pseudoautosomal region 1 (PAR1) of chromosomes X (Xp22.33) and Y (Yp11.32). 
The loss of SHOX gene functionality is assumed to be responsible for the Leri-Weill syndrome formation and the disproportionate short 
stature (DSS). The SHOX gene rearrangements constitute the majority of cases of gene functionality loss. Therefore, a practical applica-
tion of the method, which allows for the diagnostics of the gene rearrangements, becomes a primary issue. With such an assumption, the 
MLPA technique (multiplex ligation — dependent probe amplification) becomes the method of choice.
Material and methods: DNA samples were evaluated in the study by means of the MLPA method. The DNA was isolated from peripheral 
blood of sixty-three (63) 46,XX patients with short stature. 
Results: Out of the examined patients, deletions within the SHOX gene were found in five (5) patients, and duplication at the PAR1 
regulatory region of the SHOX gene in one (1) case. 
Conclusions: The obtained results confirm the opinion that the MLPA method, while enabling the diagnostics of the etiopathogenetic 
factor of short stature, identified in approximately 9.5% of cases, is a useful tool in the diagnostics of SHOX gene deletion and duplication. 
(Endokrynol Pol 2016; 67 (4): 397–402)
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Streszczenie
Wstęp: Gen SHOX został zmapowany w regionie pseudoautosomalnym 1 (PAR1) chromosomów X (Xp22.33) i Y (Yp11.32). Utratę funkcji 
genu SHOX czyni się odpowiedzialną za powstanie zespołu Leri-Weill i nieproporcjonalnie niski wzrost (DSS, disproportionate short stature). 
Delecje genu SHOX stanowią większość przypadków utraty funkcji genu. Z tego tytułu sprawą pierwszoplanową staje się aplikacja do 
praktyki diagnostycznej metody, która umożliwia diagnostykę rearanżacji tego genu. Przy takim założeniu technika MLPA (multiplex 
ligation — dependent probe amplification) staje się metodą z wyboru.
Materiały i metody: W badaniach analizowano z użyciem metody MLPA próbki DNA wyizolowanego z krwi obwodowej 63 pacjentek 
46,XX z niskorosłością. 
Wyniki: Spośród przebadanych pacjentek u 5 wykryto delecje w obrębie genu SHOX, u jednej pacjentki wykryto duplikację w regionie 
regulatorowym PAR1 genu SHOX. 
Wnioski: Uzyskane wyniki potwierdzają opinię, że metoda MLPA, umożliwiając diagnostykę czynnika etiopatogenetycznego niskorosłości 
w około 9,5 % przypadków, jest użytecznym narzędziem w diagnostyce delecji i duplikacji genu SHOX. (Endokrynol Pol 2016; 67 (4): 397–402)
Słowa kluczowe: niskorosłość; MLPA; SHOX
Introduction
The height of a short patient is below the third centile 
or < –2SD for a given age, sex, and race. Short stature 
is a multi-causal symptom which may be genetically 
determined. The frequent causes of short stature are 
rearrangements of the SHOX (short stature homeobox) 
gene on chromosome X or Y at PAR1 region (Xp22.33 
and Yp11.32). The presence of abnormalities within 
the SHOX gene was demonstrated in patients with the 
Leri-Weill syndrome or Turner’s syndrome, as well as in 
patients with idiopathic short stature (ISS). Rearrange-
ments in a non-coding sequence, localised in a certain 
distance from the SHOX gene, at the regulatory region 
in size of up to 346 kbp (locus Xp22.32), may also disturb 
normal gene expression [1]. 
The penetration of SHOX deficit is high, but its 
clinical manifestation is variable. Growth disorders are 
initiated in the first years of life. The body length of 
a newborn after birth is characterised by a slight deficit 
which, however, increases when the child is at kinder-
garten age. In female patients affected by the above-
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mentioned rearrangement, no normal pubertal spurt is 
observed. The presence of certain small morphological 
abnormalities plus subtle radiological symptoms are 
significant markers, indicating the necessity of genetic 
studies [2–5].
The SHOX gene
The SHOX gene has been mapped during studies on 
deletions in the short arm of chromosome X, accompa-
nied by short stature. The studies were performed by 
Rao [6] and, independently, by Ellison et al. [7], who pro-
vided the studied gene with the name of PHOG (pseu-
doautosomal homeobox-containing osteogenic gene). The 
gene is localised at the terminal part of the short arms 
of chromosomes X and Y at the telomere sub-region 
of the PAR1 pseudoautosomal region, and comprises 
2.6 Mbp. The PAR1 region comprised inactivation-
avoiding genes [8, 9]. The SHOX gene is then active 
on both copies of chromosome X in women and on 
chromosomes X and Y in men. It causes the occur-
rence of disease phenotypes in cases of a modified 
number of pseudoautosomal gene copies, i.e. in the 
case of occurrence of aneuploidy or polysomy of the 
sex chromosomes (e.g. 45,X, 47,XXX, 47,XXY, 47,XYY). 
The PAR1 region undergoes an obligatory crossing over 
process between chromosomes X and Y, which may 
induce abnormalities, promoting an emergence of 
mutations in the SHOX region in the course of male 
meiosis [10].
The SHOX gene is built of two motifs: the first 
one encodes a homeodomain, which enables the spe-
cific DNA binding with the protein and ensures the 
transactivation of genes. The other motif encodes the 
C-terminal OAR domain, which is important for the 
SHOX gene activity. The mRNA of the SHOX gene is 
encoded by seven exons (1-5, 6a and 6b), corresponding 
to approximately 49 kbp of genomic DNA. An alterna-
tive splicing provides the following two products: the 
OAR domain containing SHOXa and SHOXb, its shorter 
version, which, while missing the OAR domain, does 
not activate the transcription process. The functional-
ity of SHOXb has not yet received sufficient attention 
of researchers and thus remains rather obscure [7, 11].
The SHOX gene functions are impaired in almost 
100% of Turner ’s syndrome cases, 50–90% of Leri-
Weill syndrome cases, and in 2–15% of patients with 
idiopathic short stature (ISS) [4, 12, 13]. The SHOX 
gene plays an important role in the development of 
the bone system [7]. The homeodomain protein of the 
SHOX gene plays the function of transcription activator, 
which controls the expression of genes responsible for 
the growth process. A loss of gene copy or mutation of 
one gene allele causes shortening of metacarpal bone IV, 
abnormalities in facial skeleton structure, gothic palate, 
short, broad neck, and scoliosis (however, often in cases 
of Leri-Weill syndrome, as well as in Turner syndrome). 
The most frequent rearrangements of the SHOX 
gene include deletions of various sizes, encompassing 
the SHOX gene or the regulatory region [14]. Deletions 
stand for approximately 80% of all rearrangements [15]. 
The loss of both SHOX alleles brings about a complete 
deficit of SHOX protein and an extreme phenotype of 
osteodysplasia, described as Langer syndrome [16]. 
An additional copy of the SHOX gene, which occurs 
in this case of polysomy, may result in higher patient’s 
stature [17, 18].
Short stature may also be caused by partial duplication 
of the SHOX gene and of the regulatory region [18, 19]. 
The rate of patients with identified duplications 
amounts to 7.3% of those with Lerie-Weill dyschon-
drosteosis (LWD) and 1% of patients with idiopathic 
short stature (ISS). The clinical symptoms associated 
with partial SHOX duplication depend on the physi-
cal localisation of the duplicated sequence, which may 
cause gene expression decrease. Additional copies of the 
gene or its fragments in the neighbourhood of the nor-
mal gene may change the distance between the gene, 
the SHOX promoter, and the regulatory region, which 
may in turn result in gene expression reduction [19].
Diagnostics 
Cytogenetic study is a commonly used diagnostic 
method to identify chromosome X monosomy or struc-
tural aberration. This method is characterised by low 
cost and the possibility of simultaneous evaluation of 
the entire genome organisation in the studied subject. 
Tests that enable the identification of selected chromo-
some aberrations by other methods are increasingly 
common: FISH (fluorescence in situ hybridization), 
QF-PCR (quantitative fluorescence polymerase chain 
reaction), and MLPA (multiplex ligation-dependent 
probe amplification) [20–32]. These methods, having 
comparable efficacy and diagnostic reliability, making 
it possible to diagnose SHOX gene rearrangements [33]. 
Studies employing comparative genomic hybridisation 
(CGH) are expensive but also are more often used, al-
lowing for simultaneous evaluation of tens of thousands 
of sequences. In our conditions, with the results of 
cytogenetic study, excluding the presence of structural 
aberrations on the Xp arm, the diagnosis of which could 
be possible at the level of a single chromosome band, 
we decided to apply the MLPA technique [20–22]. 
Material and methods
The presented research project was approved by the 
Bioethical Committee of the Medical University in 
Lodz, No. RWS-1173/11. Patients or legal guardians 
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expressed their conscious consent to the tests. Sixty-
three (63) female patients with normal 46,XX karyotype 
and short stature were qualified to the study, all of 
them inhabitants of the Lodz Province. Some of the 
patients demonstrated such features as: compromised 
physique proportions, asymmetric bodies, and changed 
facial skeleton proportions, as well as features charac-
teristic for patients with chromosome X monosomy, 
i.e. primary amenorrhoea, dysmorphic facial features, 
shortened metacarpal bone IV, short and broad neck, 
and low posterior hairline.
Cytogenetic studies of chromosomes employed 
the classical “band after band” analysis with a minimal 
resolution of 550. DNA was isolated from 6 ml of whole 
blood, collected under vacuum on EDTA. Genomic 
DNA from the patients was collected by the column 
isolation method, using a Qiamp DNA Blood Midi 
Kit (Qiagen, Germany). The obtained DNA concen-
trations amounted to 50–500 ng in 1 μl of TE buffer. 
The samples were analysed by the MLPA method, 
using SALSA MLPA probe mix (P018-F1 SHOX probes 
of MRC-Holland), following the manufacturer ’s 
instructions. In the first step, DNA was denatured 
following by an overnight incubation period with 
a mixture of MLPA probes. MLPA probes consist of 
two oligonucleotides, each containing a single pair of 
PCR primers used for amplification. The two probe 
oligonucleotides hybridise to immediately adjacent 
target sequences. Only when both oligonucleotides 
hybridised to their adjacent targets can they be ligated 
during the ligation reaction, and they can be exponen-
tially amplified during the subsequent PCR reaction. 
The resulting amplification products of SALSA MLPA 
kits range between 130 and 480 bp in length. The PCR 
product was separated by the capillary electrophoresis 
method. The obtained results were analysed by means 
of GeneMarker V1.70 software (SoftGenetics, LLC, State 
College, USA). The probe signal level in the analysed 
sample was comparable to the probe signal level in the 
synthetic control. The values of relative probe fluores-
cence (the relative peak values) of normal samples were 
within the range 0.7–1.3. The values above 1.3 indicated 
duplication, while those below 0.7 were informative of 
deletion (Fig. 1). 
Results
Among DNA samples, obtained from 63 patients, in 
57 there were no SHOX gene rearrangements that 
wereidentifiable by means of the MLPA method and 
commercially available probes. Abnormalities in the 
SHOX gene were identified in six patients, including 
five cases of deletion and one case of duplication. 
Deletions in exon 5 were found in two patients. One 
of the results indicated deletions in exons 5 and 6a. 
The fourth patient demonstrated deletion in exon 
4 and another one in exon 6. In one patient, duplication 
was observed, including the Xp22.33-PAR1 regulatory 
region and CRLF2 and CSF2RA genes, located next to 
the region (Fig. 2, Table I).
Discussion
The MLPA enables a simultaneous analysis of a big 
number of samples, with a relatively little effort and 
small equipment needs. This method ensures study 
results to be obtained within 24 hours [20]. 
Among chromosomal aberrations of the PAR1 re-
gion, 80% are deletions. The incidence of heterozygotic 
deletions of the SHOX gene are estimated at 2–15% of 
idiopathic short stature cases [9]. This has been con-
firmed by the presented studies, where the obtained 
result (i.e. the proportion of heterozygotic deletions of 
the SHOX gene) amounted to 9.5% of cases.
The analysis of the SHOX gene was completed by an 
analysis of the Xp22.33-PAR1 region, localised beyond 
Figure 1. Schematic MLPA reaction. Sources: Company Website 
MRC Holland, http://www.mlpa.com/WebForms/WebFormMain.
aspx?Tag=_wl2zCji-rCGANQgZPuTixsEyIW1MscfzuKj2NDF
Yc-g. Access: 05.05.2016
Rycina 1. Schemat reakcji MLPA. Źródło: strona internetowa 
firmy MRC Holland, http://www.mlpa.com/WebForms/
WebFormMain.aspx?Tag=_wl2zCji-rCGANQgZPuTixsEyIW
1MscfzuKj2NDFYc-g; data pobrania: 05.05.2016
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the SHOX gene; it has been suggested that this is the 
regulatory region of transcription. Deletions may occur 
in that region with the incidence rate of cases at 4–16% 
[13, 14, 34–36]. It means that 16% of all deletions may 
remain unidentified by the diagnostic method that does 
not encompass this particular region. 
The possibility to identify SHOX gene duplications 
or its fragments, as well as duplications of the regulatory 
region, seems equally justified. Benito-Sanz et al. carried 
out studies employing the MLPA method in a group of 
735 patients, identifying total duplications of the SHOX 
gene in 0.5% of cases, partial duplications encompassing 
several exons in 1.4% of patients, and duplications of the 
regulatory region in 2.0% of cases [19]. The presented 
study seems to confirm their results. In the presented 
study, one of the patients with idiopathic short stature 
demonstrated duplication, encompassing the Xp22.33-
PAR1 regulatory region and CRLF2 and CSF2RA genes, 
which comprises 1.8% of the studies cases. As expected, 
mutations within the regulatory region provide a simi-
lar clinical picture as those within the SHOX gene. This 
is probably associated with impaired gene transcription 
and reduced volume of normal SHOX protein. 
In order to evaluate the diagnostic usefulness of 
the MLPA method, the following four aspects should 
be considered: the sensitivity of the method, its clinical 
limitations, the associated labour intensity, and the eco- 
nomic aspect. In many publications, the sensitivity and 
specificity of the MLPA method, regarding the identifi- 
cation of the most frequent rearrangements, amounted 
to 100% [31,32,40]. The frequency of failures resulting, 
among others, from poor DNA quality varied from 0.8% 
to 4.4% [30–32]. Many authors emphasise the fact that 
the MLPA method is sensitive to DNA quality. The rate of 
failures, when carrying out the test, was comparable with 
the rate of studies, in which neither the QF-PCR method 
nor the FISH method gave informative results, which 
were 0.1–3.7% and 0.0–4.9%, respectively [23–29, 40]. 
Taking into account the above observations, and ensur-
ing DNA of good quality, the MLPA technique may be 
recommended as diagnostic standard.
Conclusions
A reliable and early identification of the SHOX gene 
rearrangement allows for optimisation of the growth 
hormone therapy onset and duration, which helps 
achieve the highest relative indices of body height in-
crease while preventing stature deficits to be revealed 
in the pre- and early school period [41]. It enables the 
hormonal replacement therapy to be initiated at close 
to the optimal time point. It also allows for an optimal 
introduction of psychological and educational sup-
Figure 2. Selected results of MLPA reactions: A. Deletion 
in exon 4; B. Deletion in exons 5, 6a; C. Deletion in exon 6; 
D. Duplication in the Xp22.33-PAR1 regulatory region and in 
the CRLF2 and CSF2RA genes
Rycina 2. Wybrane wyniki reakcji MLPA. A. Delecja w eksonie 4; 
B. Delecja w eksonach: 5, 6a; C. Delecja w eksonie 6; D. Duplikacja 
w regionie regulatorowym Xp22.33-PAR1 oraz genach CRLF2 
oraz CSF2RA
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Table I. The obtained results: above 1.3 — duplication; below 0.7 — deletion
Tabela I. Uzyskane wyniki; powyżej 1,3 — duplikacja; poniżej 0,7 — delecja
Locus Patient
1 2 3 4 5 6
Xp22.33-PAR1 1.011 1.051 0.951 1.025 1.110 1.022
4 kb before SHOX-PAR1 1.162 1.037 0.978 1.023 1.026 1.063
Exon 1 PAR1 0.889 0.879 1.045 0.904 1.021 0.978
Exon 2 PAR1 0.878 0.985 1.150 1.105 1.111 0.948
Exon 3 PAR1 1.014 0.965 1.001 0.901 1.024 1.154
Exon 4 PAR1 1.121 0.542 1.012 1.128 1.078 1.134
Exon 5 PAR1 0.932 0.925 0.658 0.513 0.528 1.113
Exon 6 (6a) PAR1 0.984 0.965 0.913 0.504 1.054 0.520
Intron 6 PAR1 0.952 0.845 1.002 1.154 1.199 1.158
Intron 6 PAR1 0.987 0.963 0.956 0.945 0.875 0.846
Xp22.33-PAR1 0.874 0.982 1.015 1.198 1.201 0.987
Xp22.33-PAR1 0.932 0.952 0.994 0.965 1.025 1.032
Xp22.33-PAR1 0.923 0.987 1.023 0.885 1.021 0.954
Xp22.33-PAR1 1.025 1.147 0.964 0.948 1.085 1.112
Xp22.33-PAR1 — the regulatory region 1.087 1.096 0.998 0.985 1.010 0.012
Xp22.33-PAR1 — the regulatory region 1.456 1.013 1.102 1.098 1.002 0.982
Xp22.33-PAR1 — the regulatory region 1.438 1.154 1.069 0.958 0.948 0.892
Xp22.33-PAR1 — the regulatory region 1.514 1.002 1.051 1.145 1.005 1.009
Xp22.33-PAR1 — the regulatory region 1.531 0.951 0.956 1.023 1.023 1.056
Xp22.33-PAR1 1.442 1.059 1.007 1.195 0.948 1.085
Xp22.33-PAR1 1.522 1.002 1.021 1.048 1.063 1.145
Xp22.33-PAR1 1.467 0.879 1.045 1.065 1.023 1.095
Xp22.33-PAR1 1.522 1.004 0.948 1.201 0.987 1.144
CRLF2 1.435 1.011 0.956 1.025 1.032 1.165
CSF2RA 1.423 1.063 0.942 1.010 0.892 0.888
IL3RA 0.965 1.023 0.894 1.056 0.951 1.154
ASMT 0.854 1.062 1.145 1.111 1.117 0.945
ZBED1 0.869 1.021 1.146 1.025 0.932 0.874
ARSF 0.962 0.987 1.063 1.135 0.984 0.896
PRKX 0.935 0.978 1.185 1.165 0.846 0.945
NLGN4X 1.151 0.948 1.094 1.085 0.951 0.013
KAL1 1.025 1.154 1.023 0.985 0.965 0.966
FANCB 1.063 0.925 0.196 0.845 1.051 0.962
AIFM1 1.096 0.935 1.125 0.961 1.062 0.947
Xq28-PAR2 0.965 0.962 1.006 1.012 1.145 1.052
port to prevent differences in educational and social 
status opportunities. The obtained results confirm 
the view that the MLPA method, while enabling the 
diagnostics of the aetiopathogenetic factor of short 
stature, identified in approximately 10% of cases, is 
a useful tool in the diagnostics of SHOX gene deletion 
and duplication. 
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